Valuation: Natera, Inc.

Market Cap 56.02B 49.92B 45.78B 41.6B 78.21B 5,294B 79.99B 547B 219B 2,802B 210B 206B 8,876B P/E 2026 *
-272x
P/E 2027 * -3,486x
Enterprise Value 54.93B 48.95B 44.89B 40.79B 76.69B 5,191B 78.44B 537B 215B 2,748B 206B 202B 8,704B EV / Sales 2026 *
18.9x
EV / Sales 2027 * 15.5x
Free-Float
97.25%
Yield 2026 *
-
Yield 2027 * -
1 day+0.62%
1 week-4.82%
Current month-5.62%
1 month-4.71%
3 months+44.63%
6 months+88.65%
Current year+70.69%
1 week 369.51
Extreme 369.51
436.19
1 month 369.51
Extreme 369.51
437.41
Current year 181
Extreme 181
437.41
1 year 181
Extreme 181
437.41
3 years 40.61
Extreme 40.61
437.41
5 years 26.1
Extreme 26.1
437.41
10 years 7.35
Extreme 7.35
437.41
Manager TitleAgeSince
Chief Executive Officer 47 2019-01-01
President 46 2023-08-31
Director of Finance/CFO 45 2017-01-31
Director TitleAgeSince
Chairman 53 2015-04-30
Director/Board Member 53 2006-12-31
Director/Board Member 47 2019-01-01
Date Insider Type Main position Quantity % Market Cap. Importance
10/15/26 Exercice

Founder

150,000 0.1041%
10/7/26 Don

Founder

-6,000 0.0042%
10/1/26 Sell

Chief Executive Officer

-1,273 0.0009%
Change 5-day change 1-year change 3-year change Capi.($)
+0.62%-4.82%+97.26%+814.90% 56.02B
-12.53%-12.26%+1.94%+13.82% 117B
+10.34%+13.50%+10.65%+121.24% 96.69B
+1.44%+1.61%-4.61%+85.70% 30.77B
+3.92%+11.06%+42.64%+74.95% 28.74B
+3.49%+5.41%+42.97%+90.93% 27.18B
+9.58%+11.52%+45.12%+432.14% 21.23B
+2.11%-3.44%-20.07%-16.77% 19.49B
+0.26%-0.77%-6.83%+29.88% 16.82B
-0.06%+19.60%+108.42% - 14.54B
Average +3.25%+2.34%+31.75%+182.98% 42.84B
Weighted average by Cap. +3.80%+1.21%+25.64%+182.67%

Financials

2026 *2027 *
Net sales 2.91B 2.59B 2.38B 2.16B 4.06B 275B 4.16B 28.43B 11.4B 146B 10.92B 10.69B 461B 3.52B 3.14B 2.88B 2.61B 4.91B 332B 5.02B 34.36B 13.78B 176B 13.21B 12.92B 557B
Net income -203M -181M -166M -151M -284M -19.21B -290M -1.99B -796M -10.17B -763M -747M -32.21B -8.5M -7.58M -6.95M -6.31M -11.87M -803M -12.14M -83.04M -33.29M -425M -31.91M -31.23M -1.35B
Net Debt -1.09B -970M -890M -808M -1.52B -103B -1.55B -10.63B -4.26B -54.45B -4.09B -4B -172B -1.4B -1.25B -1.15B -1.04B -1.96B -133B -2B -13.71B -5.5B -70.23B -5.27B -5.16B -222B
Projected Income Statement - Annual - Natera, Inc.
Logo Natera, Inc.
Natera, Inc. provides cell-free DNA (cfDNA) and genetic testing, dedicated to oncology, women’s health, and organ health. The Company's cfDNA technology platform combines novel molecular biology techniques with bioinformatics software and artificial intelligence. It has leveraged its platform to develop non-invasive prenatal test on the market (Panorama), the first tumor-specific assay for truly individualized cancer care (Signatera), best-in-class rejection assessment for kidney transplantation (Prospera) and others. In the women’s health space, it develops and commercializes non- or minimally- invasive tests to evaluate risk for, and thereby enable early detection of, a range of genetic conditions, such as Down syndrome. In oncology, it is focused on detecting molecular residual disease and recurrence monitoring in solid tumors, among others. In organ health, it offers tests to assess kidney, heart, and lung transplant rejection as well as genetic testing for chronic kidney disease.
Employees
6,138
Date Price Change Volume
26-11-04 US$391.03 +0.62% 2,760,780
26-11-03 US$388.63 +2.56% 3,881,474
26-11-02 US$378.92 -8.54% 2,627,909
26-10-30 US$414.30 -4.98% 2,432,183
26-10-29 US$436.00 +2.73% 1,326,459
Trader
Investor
-
Global
-
Quality
ESG MSCI
BB
MarketScreener Ratings - Natera, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
391.03USD
Average target price
416.39USD
Spread / Average Target
+6.48%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Natera, Inc.
  1. Stock Market
  2. Stocks
  3. NTRA Stock